DIQUAS Ophthalmic Solution 3% Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

diquas ophthalmic solution 3%

santen pharma malaysia sdn. bhd. - diquafosol sodium -

COSOPT-S OPHTHALMIC SOLUTION Singapore - English - HSA (Health Sciences Authority)

cosopt-s ophthalmic solution

santen pharmaceutical asia pte. ltd. - dorzolamide hydrochloride 22.26mg/ml eqv. dorzolamide base; timolol maleate 6.83mg/ml eqv. timolol base - solution, sterile - dorzolamide hydrochloride 22.26mg/ml eqv. dorzolamide base 20mg/ml; timolol maleate 6.83mg/ml eqv. timolol base 5mg/ml

TRUSOPT OPHTHALMIC SOLUTION 2% Singapore - English - HSA (Health Sciences Authority)

trusopt ophthalmic solution 2%

santen pharmaceutical asia pte. ltd. - dorzolamide hcl eqv dorzolamide - solution - dorzolamide hcl eqv dorzolamide 2%

Eybelis ophthalmic solution 0.002% Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

eybelis ophthalmic solution 0.002%

santen pharma malaysia sdn. bhd. - omidenepag isopropyl -

Saflutan 15 micrograms/ml eye drops, solution, single-dose container Malta - English - Medicines Authority

saflutan 15 micrograms/ml eye drops, solution, single-dose container

santen oy niittyhaankatu 20, 33720 tampere, finland - tafluprost - eye drops, solution - tafluprost 15 µg/ml - ophthalmologicals

Saflutan 15 micrograms/ml, eye drops, solution in single-dose container Ireland - English - HPRA (Health Products Regulatory Authority)

saflutan 15 micrograms/ml, eye drops, solution in single-dose container

santen oy - tafluprost - eye drops, solution in single-dose container - 15 microgram(s)/millilitre - prostaglandin analogues1); tafluprost - antiglaucoma preparations and miotics, prostaglandin analogues - as monotherapy in patients:  who would benefit from preservative free eye drops  insufficiently responsive to first line therapy  intolerant or contra-indicated to first line therapy. as adjunctive therapy to beta-blockers.

Timoptol 0.25% w/v eye drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

timoptol 0.25% w/v eye drops, solution

santen oy - timolol base - eye drops, solution - 0.25 percent weight/volume - beta blocking agents1); timolol - it is a beta-adrenoreceptor blocking agent used topically in the reduction of elevated intra-ocular pressure in various conditions including the following: patients with ocular hypertension; patients with chronic open-angle glaucoma including aphakic patients; some patients with secondary glaucoma.

Timoptol 0.5% w/v eye drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

timoptol 0.5% w/v eye drops, solution

santen oy - timolol base - eye drops, solution - 0.5 percent weight/volume - beta blocking agents1); timolol - it is a beta-adrenoreceptor blocking agent used topically in the reduction of elevated intra-ocular pressure in various conditions including the following: patients with ocular hypertension; patients with chronic open-angle glaucoma including aphakic patients; some patients with secondary glaucoma.

TRUSOPT 20 mg/ml eye drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

trusopt 20 mg/ml eye drops, solution

santen oy - dorzolamide hydrochloride - eye drops, solution - 20 milligram(s)/millilitre - dorzolamide - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors, dorzolamide - it is indicated: as adjunctive therapy to beta-blockers, as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated, in the treatment of elevated intra-ocular pressure in: ocular hypertension, open-angle glaucoma, pseudoexfoliative glaucoma.

TRUSOPT Preservative-Free 20 mg/ml eye drops, solution in single-dose container Ireland - English - HPRA (Health Products Regulatory Authority)

trusopt preservative-free 20 mg/ml eye drops, solution in single-dose container

santen oy - dorzolamide - eye drops, solution in single-dose container - 20 milligram(s)/millilitre - carbonic anhydrase inhibitors; dorzolamide - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors, dorzolamide - it l is indicated: as adjunctive therapy to beta-blockers; as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated; in the treatment of elevated intra-ocular pressure in: ocular hypertension; open-angle glaucoma; pseudoexfoliative glaucoma.